Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S CHIN YEE

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1740424563
CMS profile
34172
Location
ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$198,843.89

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S CHIN YEE

NPI 1740424563 · CMS profile ID 34172

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

ATLANTA, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740424563?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S CHIN YEE, NPI 1740424563, CMS profile ID 34172. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740424563?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID S CHIN YEE, NPI 1740424563, CMS profile ID 34172. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740424563?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID S CHIN YEE, NPI 1740424563, CMS profile ID 34172, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1740424563?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $198,843.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alcon Vision LLC $24.9904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207415399 CMS
Regeneron Healthcare Solutions, Inc. $26.9304/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889646 CMS
Regeneron Healthcare Solutions, Inc. $30.3304/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889640 CMS
Regeneron Healthcare Solutions, Inc. $36.0004/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889642 CMS
Regeneron Healthcare Solutions, Inc. $11.0404/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889644 CMS
Astellas Pharma US Inc $134.2204/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238637806 CMS
Regeneron Healthcare Solutions, Inc. $7,520.0004/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212889638 CMS
Regeneron Healthcare Solutions, Inc. $449.3504/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889634 CMS
Regeneron Healthcare Solutions, Inc. $287.0204/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889636 CMS
Regeneron Healthcare Solutions, Inc. $115.2204/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889632 CMS
Bausch & Lomb Americas Inc. $99.6004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254771358 CMS
Regeneron Healthcare Solutions, Inc. $198.1704/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889630 CMS
Genentech USA, Inc. $28.3204/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211507638 CMS
Regeneron Healthcare Solutions, Inc. $198.1704/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889628 CMS
Apellis Pharmaceuticals, Inc. $27.2204/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253192622 CMS
Regeneron Healthcare Solutions, Inc. $572.9604/02/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889626 CMS
Regeneron Healthcare Solutions, Inc. $22.1904/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889620 CMS
Regeneron Healthcare Solutions, Inc. $8.9204/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889622 CMS
Regeneron Healthcare Solutions, Inc. $5,640.0004/01/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212889624 CMS
Apellis Pharmaceuticals, Inc. $30.3903/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253192616 CMS
Regeneron Healthcare Solutions, Inc. $336.9803/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889616 CMS
Regeneron Healthcare Solutions, Inc. $157.0703/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889618 CMS
ANI Pharmaceuticals, Inc. $19.0303/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248590300 CMS
Apellis Pharmaceuticals, Inc. $1,500.0003/25/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1253192618 CMS
Astellas Pharma US Inc $37.8203/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238757292 CMS
ABBVIE INC. $20.5403/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201652074 CMS
Astellas Pharma US Inc $22.8303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238763912 CMS
Regeneron Healthcare Solutions, Inc. $676.9803/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889614 CMS
Regeneron Healthcare Solutions, Inc. $1,880.0003/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212889608 CMS
Regeneron Healthcare Solutions, Inc. $409.2403/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889610 CMS
Regeneron Healthcare Solutions, Inc. $25.5003/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889612 CMS
Regeneron Healthcare Solutions, Inc. $4,700.0002/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212889598 CMS
Regeneron Healthcare Solutions, Inc. $72.0002/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889600 CMS
Regeneron Healthcare Solutions, Inc. $15.4802/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889602 CMS
Regeneron Healthcare Solutions, Inc. $72.0002/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889604 CMS
Regeneron Healthcare Solutions, Inc. $15.4802/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889606 CMS
Genentech USA, Inc. $3,375.0002/26/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1211507632 CMS
ANI Pharmaceuticals, Inc. $74.4102/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248651040 CMS
Regeneron Healthcare Solutions, Inc. $4,700.0002/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212889594 CMS
Regeneron Healthcare Solutions, Inc. $7,520.0002/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212889596 CMS
ANI Pharmaceuticals, Inc. $17.9902/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248586989 CMS
Regeneron Healthcare Solutions, Inc. $1,880.0002/20/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1212889586 CMS
Regeneron Healthcare Solutions, Inc. $596.9202/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889588 CMS
Regeneron Healthcare Solutions, Inc. $562.4602/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889590 CMS
Regeneron Healthcare Solutions, Inc. $34.6202/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889592 CMS
Regeneron Healthcare Solutions, Inc. $30.4302/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889580 CMS
Regeneron Healthcare Solutions, Inc. $124.9902/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889582 CMS
Regeneron Healthcare Solutions, Inc. $27.7702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212889584 CMS
Regeneron Healthcare Solutions, Inc. $389.8802/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889578 CMS
Regeneron Healthcare Solutions, Inc. $57.8602/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1212889572 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,611.21 77
PY2020 $17,690.30 42
PY2021 $35,552.53 77
PY2022 $73,412.66 142
PY2023 $176,403.10 200
PY2024 $271,580.02 286
PY2025 $198,843.89 220

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $98,971.36 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 12/23/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184279708
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,647.08 12/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,617.42 12/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,591.22 12/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 12/15/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,793.00 12/15/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184275517
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,577.52 12/11/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184270697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 11/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 11/19/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184261887
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/29/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/29/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184254339
Principal investigator 1 Notal Vision, Inc. $30.00 10/14/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740642
Principal investigator 1 Notal Vision, Inc. $60.00 10/14/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740644
Principal investigator 1 Notal Vision, Inc. $30.00 10/14/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,391.94 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245371
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,391.94 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245375
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,391.94 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,764.35 10/03/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184245379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 09/17/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184237762
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740624
Principal investigator 1 Notal Vision, Inc. $60.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740626
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740630
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740632
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740634
Principal investigator 1 Notal Vision, Inc. $60.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740636
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740638
Principal investigator 1 Notal Vision, Inc. $30.00 09/08/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 07/18/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184217374
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,365.74 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,365.74 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,793.00 07/16/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184215096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 06/02/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 06/02/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184201169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 04/23/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,738.16 04/23/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184186229
Principal investigator 1 Notal Vision, Inc. $60.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740598
Principal investigator 1 Notal Vision, Inc. $60.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740600
Principal investigator 1 Notal Vision, Inc. $60.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740602
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740604
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740608
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740610
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740612
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740614
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740616
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740618
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740620
Principal investigator 1 Notal Vision, Inc. $30.00 04/22/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740622
Principal investigator 1 Notal Vision, Inc. $60.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740580
Principal investigator 1 Notal Vision, Inc. $60.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740582
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740586
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740588
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740590
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740592
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740594
Principal investigator 1 Notal Vision, Inc. $30.00 04/21/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740596
Principal investigator 1 Notal Vision, Inc. $60.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740570
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740572
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740574
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740576
Principal investigator 1 Notal Vision, Inc. $30.00 04/15/2025 Non-covered Recipient Entity
Georgia Retina PC
NRICH No dispute reported 06/30/2026 1242740578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,963.72 03/12/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,963.72 03/12/2025 Non-covered Recipient Entity
GEORGIA RETINA P C
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184171076